Related Experiment Video
Updated: Jan 26, 2026

Author Spotlight: Enhancing Candida albicans Detection in Catheter Infections Using Fluorescent Protein Tagging
Published on: March 22, 2024
NDV-3A vaccination prevents C. albicans colonization of jugular vein catheters in mice
Abdullah Alqarihi1, Shakti Singh1, John E Edwards1,2
1Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
Abstract:
NDV-3A, a novel fungal vaccine undergoing clinical trials, contains a recombinant version of the Candida albicans rAls3 N-terminus protein (rAls3p-N) in aluminum hydroxide. In a Phase 1b/2a clinical trial, NDV-3A protected women from recurrent vulvovaginal candidiasis. Here, we reveal that active immunization in mice with NDV-3A induces high titers of anti-rAls3p-N antibodies that interfere with C. albicans ability to adhere to and invade endothelial cells, and form biofilm in vitro. Anti-rAls3p-N antibodies also significantly inhibit yeast dispersal from the hyphal layers of biofilms. Compared to placebo, NDV-3A vaccination inhibited C. albicans dissemination to kidneys and prevented colonization of central venous catheters in mice. Overall, these preclinical studies suggest that NDV-3A may serve as an immunotherapeutic strategy for prevention of infections on indwelling medical devices.
Insights
A novel fungal vaccine, NDV-3A, demonstrated protection against recurrent vulvovaginal candidiasis in women. Preclinical studies show it prevents Candida albicans infections and biofilm formation, suggesting potential for medical devices.
Area of Science:
- Mycology
- Immunology
- Vaccinology
Background:
- Recurrent vulvovaginal candidiasis remains a clinical challenge.
- Candida albicans employs Als3 protein for adhesion and invasion.
- Novel immunotherapies are needed for fungal infections.
Purpose of the Study:
- To evaluate the preclinical efficacy of NDV-3A, a fungal vaccine candidate.
- To investigate the mechanism of action of anti-rAls3p-N antibodies.
- To assess NDV-3A's potential in preventing device-associated candidiasis.
Main Methods:
- Active immunization of mice with NDV-3A.
- Measurement of anti-rAls3p-N antibody titers.
- In vitro assays for C. albicans adhesion, invasion, and biofilm formation.
- In vivo studies assessing fungal dissemination and catheter colonization.
Main Results:
- NDV-3A induced high titers of neutralizing anti-rAls3p-N antibodies.
- Antibodies inhibited C. albicans adhesion, invasion, and biofilm dispersal.
- Vaccination prevented systemic C. albicans dissemination and catheter colonization in mice.
Conclusions:
- NDV-3A elicits protective immunity against C. albicans.
- The vaccine's mechanism involves antibodies targeting rAls3p-N.
- NDV-3A shows promise as an immunotherapeutic for preventing candidiasis and device-related infections.
Related Concept Videos
Vaccinations
The Colonization of Land
Cancer Prevention
Some...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Veins
Structure of Veins:
The structure of veins is specifically designed to assist in the low-pressure transportation of...
Prevention of Further Absorption of Poison

